We have located links that may give you full text access.
Journal Article
Randomized Controlled Trial
Improving Patient-Centered Care by Assessing Patient Preferences for Multiple Sclerosis Disease-Modifying Agents: A Stated-Choice Experiment.
Permanente Journal 2017
CONTEXT: Long-term adherence to pharmaceutical treatment for multiple sclerosis (MS) is poor. A focus on patient preferences when determining the patient's therapeutic plan may improve this experience.
OBJECTIVE: To identify factors important to patients with MS when evaluating their options for pharmaceutical agents that deliver disease-modifying therapy.
DESIGN: Stated-choice experiment to a sample of patients with MS from privately and publicly insured enrollees in a regional health plan. The experiment presented each respondent with a set of 8 drug choices for MS, asking them to select their preferred disease-modifying agent (DMA). Each respondent was randomized to 1 of 6 possible sets of 8 drug choices, for a total of 48 drug pairings in the experiment. Each choice included 2 hypothetical DMAs and a "no drug" option. Drug attributes included dosage type and modality, efficacy, relapse risk, and drug side effects.
RESULTS: The "no drug" alternative was a stronger substitute than the alternative drug when the focal drug characteristics changed, and the most important drivers of choice were type of side effects and risk of severe relapse.
DISCUSSION: The heterogeneity of our sample and the inclusion of a "no drug" alternative in the DMA choice scenarios make this study an important contribution to this body of literature. The importance of the "no drug" alternative in our results is consistent with poor long-term adherence to DMAs.
CONCLUSION: Patient-centered MS therapy using DMAs should include discussion of side effects and relapse risk.
OBJECTIVE: To identify factors important to patients with MS when evaluating their options for pharmaceutical agents that deliver disease-modifying therapy.
DESIGN: Stated-choice experiment to a sample of patients with MS from privately and publicly insured enrollees in a regional health plan. The experiment presented each respondent with a set of 8 drug choices for MS, asking them to select their preferred disease-modifying agent (DMA). Each respondent was randomized to 1 of 6 possible sets of 8 drug choices, for a total of 48 drug pairings in the experiment. Each choice included 2 hypothetical DMAs and a "no drug" option. Drug attributes included dosage type and modality, efficacy, relapse risk, and drug side effects.
RESULTS: The "no drug" alternative was a stronger substitute than the alternative drug when the focal drug characteristics changed, and the most important drivers of choice were type of side effects and risk of severe relapse.
DISCUSSION: The heterogeneity of our sample and the inclusion of a "no drug" alternative in the DMA choice scenarios make this study an important contribution to this body of literature. The importance of the "no drug" alternative in our results is consistent with poor long-term adherence to DMAs.
CONCLUSION: Patient-centered MS therapy using DMAs should include discussion of side effects and relapse risk.
Full text links
Related Resources
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app